# Apatinib Monotherapy Versus Apatinib Combined With Camrelizumab for Third-line Treatment of Metastatic Gastric Cancer

> **NCT05095636** · PHASE2 · UNKNOWN · sponsor: **Fudan University** · enrollment: 102 (estimated)

## Conditions studied

- Gastric Cancer
- Metastasis

## Interventions

- **DRUG:** Apatinib Mesylate
- **DRUG:** Camrelizumab

## Key facts

- **NCT ID:** NCT05095636
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-03-17
- **Primary completion:** 2023-03
- **Final completion:** 2023-09
- **Target enrollment:** 102 (ESTIMATED)
- **Last updated:** 2021-10-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05095636

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05095636, "Apatinib Monotherapy Versus Apatinib Combined With Camrelizumab for Third-line Treatment of Metastatic Gastric Cancer". Retrieved via AI Analytics 2026-07-31 from https://api.ai-analytics.org/clinical/NCT05095636. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*